FOx Biosystems appoints Thomas van Elzakker as its new CEO

Sep 01, 2020 | Katleen Vandersmissen

Diepenbeek (Belgium), September 1st, 2020 – FOx Biosystems’ Board of Directors announces the appointment of Thomas van Elzakker as Chief Executive Officer per 1 September 2020. Van Elzakker takes over from company co-founder Filip Delport who takes up the position of Chief Technology Officer to further develop the proprietary FOx FO-SPR technology.

FOx Biosystems was founded in 2017 as a spin-off of the MeBios research group of KU Leuven. In 2020 the company introduced its White Fox 1.0 system to the market, offering real-time, label-free analysis utilizing FOx Biosystems’ revolutionary fiber-optic biosensor technology. This innovative platform increases the efficiency of bio-pharmaceutical research and development and enables its users to generate high quality biomolecular data such as affinity data, kinetic data and concentration measurements. Investors in FOx Biosystems include Heran Partners, LRM and Gemma Frisius Fund KU Leuven.

Van Elzakker comes to FOx Biosystems with an international business management career in MedTech, having worked for corporates Philips and Medtronic as well as Dutch ophthalmology startup i-Optics. His career is characterized by building and growing business initiatives, bringing new products to market, and driving commercial success. Thomas holds an MSc in Applied Computer Science from Leiden University in the Netherlands.

“Filip Delport has done a great job as CEO, developing the technology and building an excellent team. Now that FOx enters a phase of growth and expansion the Board is very happy to welcome Thomas van Elzakker as CEO, he brings complementary experience in scaling-up technical companies and international commercial expertise to the table”, says Katleen Vandersmissen, Chair of the Board of FOx.

For more information: FOx Biosystems NV, info@foxbiosystems.com, +32 11 286 973

About Gemma Frisius Fund KU Leuven

Gemma Frisius Fund is a seed capital fund established in 1997 as a joint venture between KU Leuven, KBC Bank and BNP Paribas Fortis Private Equity. The fund stimulates the creation and growth of KU Leuven spin-off companies by providing early phase seed capital. The Gemma Frisius Fund combines academic research and technology transfer expertise with financial and investment expertise. More information:

Learn more about the Gemma Frisius Fund

Join a Heran Fund

We are open to novel investments and are always planning the next funds and investment strategies. Leave your details below and our partners will be in touch.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Pitch your company

Submit your pitch below. We receive dozens of pitches each week and process these dilligently. We might not be able to get back to you immediately.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.